Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Analysis of Antihypertensive Treatment Efficacy (ATACA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00767247
Recruitment Status : Terminated
First Posted : October 7, 2008
Last Update Posted : December 3, 2010
Sponsor:
Information provided by:
AstraZeneca

Tracking Information
First Submitted Date October 6, 2008
First Posted Date October 7, 2008
Last Update Posted Date December 3, 2010
Study Start Date May 2008
Actual Primary Completion Date February 2009   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: October 6, 2008)
Analysis of antihypertensive treatment efficacy. [ Time Frame: measurement BP: 3 visits for 3 month ]
Original Primary Outcome Measures Same as current
Change History
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Analysis of Antihypertensive Treatment Efficacy
Official Title Analysis of Antihypertensive Treatment Efficacy
Brief Summary Analysis of antihypertensive treatment efficacy.
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Case Control
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population outpatient clinics
Condition Arterial Hypertension
Intervention Not Provided
Study Groups/Cohorts 1
Male or female with arterial hypertension
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Terminated
Estimated Enrollment
 (submitted: October 6, 2008)
2000
Original Estimated Enrollment Same as current
Actual Study Completion Date February 2009
Actual Primary Completion Date February 2009   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • arterial hypertension
  • intake of Atacand before study enrollment

Exclusion Criteria:

  • hypersensitivity to candesartan or any other ingredient of Atacand
  • liver function impairment and/or cholestasis
  • severe renal insufficiency (serum creatinine > 265 µmol/L)
  • Pregnant and lactating women
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Russian Federation
Removed Location Countries  
 
Administrative Information
NCT Number NCT00767247
Other Study ID Numbers NIS-CRU-ATA-2008/1
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Andrey Strugovshchikov, Medical Director, Astra Zeneca, Russia
Study Sponsor AstraZeneca
Collaborators Not Provided
Investigators
Principal Investigator: Dmitry Zateyshchikov, MD, Prof Federal State Institution of Russian President's General Management Department
PRS Account AstraZeneca
Verification Date December 2010